Protein kinases ROCK -Developments of isoform-specific inhibitors and a method to detect active ROCK isoforms
Project/Area Number |
25440091
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Cell biology
|
Research Institution | Tokyo University of Pharmacy and Life Science |
Principal Investigator |
Yoneda Atsuko 東京薬科大学, 生命科学部, 助教 (80590372)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 蛋白質リン酸化酵素 / ROCK / がん / 細胞骨格 / 細胞運動 / 細胞外マトリクス |
Outline of Final Research Achievements |
Specific functions of two homologous protein kinases ROCK in tumor progression was needed to be revealed. This study found that a peptide derived from a ROCK2 specific endogenous inhibitor, CRMP2L, alone is capable of inhibiting cell migration and invasion of colon carcinoma cells, and that GSK3 phosphorylation of CRMP2L regulates inhibition of ROCK-dependent colon carcinoma cell migration/invasion by CRMP2L.
|
Report
(4 results)
Research Products
(9 results)